Pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer, is a highly lethal malignancy with poor prognosis and limited treatment options. Researchers from Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, together with RWJBarnabas Health, in collaboration with investigators from MD Anderson Cancer Center, discovered a novel triple immunotherapy combination.
Prateek Gulhati, a physician-scientist in the Gastrointestinal Oncology Program at Rutgers Cancer Institute and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School is the lead author of the work. He shared more about the findings published in Nature Cancer. To read the full story.